- Forbes•14 days ago
Rare Disease Week was rapidly followed by more proposals to gut the ACA healthcare and the FDA, immigration and travel bans which will decimate research and healthcare (as well as being needless and cruel), and reduce research budgets. How does this help patients?
- GlobeNewswire•16 days ago
BRISBANE, Calif., March 09, 2017-- KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, ...
- Accesswire•last month
BRISBANE, CA / ACCESSWIRE / February 13, 2017 / KaloBios Pharmaceuticals, Inc. (OTC PINK: KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, ...
KBIO : Summary for KALOBIOS PHARMACEU COM USD0.001 - Yahoo Finance
KaloBios Pharmaceuticals, Inc. (KBIO)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||1.90 - 2.50|
|52 Week Range||1.90 - 5.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.85|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|